1. RuijterE, van de KaaC, MillerG, RuiterD, DebruyneF, et al. (1999) Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev 20: 22–45.
2. DjulbegovicM, BeythRJ, NeubergerMM, StoffsTL, ViewegJ, et al. (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341: c4543.
3. VickersAJ, RoobolMJ, LiljaH (2012) Screening for prostate cancer: early detection or overdetection? Annu Rev Med 63: 161–170.
4. LichtensteinP, HolmNV, VerkasaloPK, IliadouA, KaprioJ, et al. (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78–85.
5. HemminkiK, CzeneK (2002) Age specific and attributable risks of familial prostate carcinoma from the family-cancer database. Cancer 95: 1346–1353.
6. ZeegersMP, JellemaA, OstrerH (2003) Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 97: 1894–1903.
7. EelesRA, OlamaAA, BenllochS, SaundersEJ, LeongamornlertDA, et al. (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45: 385–382, 385-391, 391e381-382.
8. GohCL, SchumacherFR, EastonD, MuirK, HendersonB, et al. (2012) Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 271: 353–365.
9. EelesRA, Kote-JaraiZ, GilesGG, OlamaAA, GuyM, et al. (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40: 316–321.
10. ShahN, SukumarS (2010) The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10: 361–371.
11. KimSD, ParkRY, KimYR, KimIJ, KangTW, et al. (2010) HOXB13 is co-localized with androgen receptor to suppress androgen-stimulated prostate-specific antigen expression. Anat Cell Biol 43: 284–293.
12. NorrisJD, ChangCY, WittmannBM, KunderRS, CuiH, et al. (2009) The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol Cell 36: 405–416.
13. GillandersEM, XuJ, ChangBL, LangeEM, WiklundF, et al. (2004) Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst 96: 1240–1247.
14. LangeEM, GillandersEM, DavisCC, BrownWM, CampbellJK, et al. (2003) Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1. Prostate 57: 326–334.
15. XuJ, DimitrovL, ChangBL, AdamsTS, TurnerAR, et al. (2005) A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet 77: 219–229.
16. ChengL, BostwickDG, LiG, WangQ, HuN, et al. (1999) Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer 85: 2017–2022.
17. GaoX, ZacharekA, SalkowskiA, GrignonDJ, SakrW, et al. (1995) Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 55: 1002–1005.
18. UchidaT, WangC, SatoT, GaoJ, TakashimaR, et al. (1999) BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer 84: 19–23.
19. GoodeEL, Chenevix-TrenchG, SongH, RamusSJ, NotaridouM, et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 42: 874–879.
20. EwingCM, RayAM, LangeEM, ZuhlkeKA, RobbinsCM, et al. (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366: 141–149.
21. KarlssonR, AlyM, ClementsM, ZhengL, AdolfssonJ, et al. (2012) A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk. Eur Urol 65: 169–76.
22. ShangZ, ZhuS, ZhangH, LiL, NiuY (2013) Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24,213 cases and 73, 631 controls. Eur Urol 64: 173–176.
23. WitteJS, MeffordJ, PlummerSJ, LiuJ, ChengI, et al. (2013) HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease. Cancer Epidemiol Biomarkers Prev 22: 675–680.
24. XuJ, LangeEM, LuL, ZhengSL, WangZ, et al. (2013) HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 132: 5–14.
25. ChenZ, GreenwoodC, IsaacsWB, FoulkesWD, SunJ, et al. (2013) The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis 34: 1260–1264.
26. HaimanCA, ChenGK, BlotWJ, StromSS, BerndtSI, et al. (2011) Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 43: 570–573.
27. HuntKA, MistryV, BockettNA, AhmadT, BanM, et al. (2013) Negligible impact of rare autoimmune-locus coding-region variants on missing heritability. Nature 498: 232–235.
28. MarigortaUM, NavarroA (2013) High trans-ethnic replicability of GWAS results implies common causal variants. PLoS Genet 9: e1003566.
29. WhiffinN, DobbinsSE, HoskingFJ, PallesC, TenesaA, et al. (2013) Deciphering the genetic architecture of low-penetrance susceptibility to colorectal cancer. Hum Mol Genet 22: 507–82.
30. ChangD, KeinanA (2012) Predicting signatures of “synthetic associations” and “natural associations” from empirical patterns of human genetic variation. PLoS Comput Biol 8: e1002600.
31. DicksonSP, WangK, KrantzI, HakonarsonH, GoldsteinDB (2010) Rare variants create synthetic genome-wide associations. PLoS Biol 8: e1000294.
32. SunX, NamkungJ, ZhuX, ElstonRC (2011) Capability of common SNPs to tag rare variants. BMC Proc 5 Suppl 9: S88.
33. Kote-JaraiZ, LeongamornlertD, TymrakiewiczM, FieldH, GuyM, et al. (2010) Mutation analysis of the MSMB gene in familial prostate cancer. Br J Cancer 102: 414–418.
34. LouH, YeagerM, LiH, BosquetJG, HayesRB, et al. (2009) Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A 106: 7933–7938.
35. Kote-JaraiZ, Amin Al OlamaA, LeongamornlertD, TymrakiewiczM, SaundersE, et al. (2011) Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet 129: 687–694.
36. Kote-JaraiZ, SaundersEJ, LeongamornlertDA, TymrakiewiczM, DadaevT, et al. (2013) Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 22: 2520–2528.
37. AndersonCA, PetterssonFH, ClarkeGM, CardonLR, MorrisAP, et al. (2010) Data quality control in genetic case-control association studies. Nat Protoc 5: 1564–1573.
38. HowieB, MarchiniJ, StephensM (2011) Genotype imputation with thousands of genomes. G3 (Bethesda) 1: 457–470.
39. HowieBN, DonnellyP, MarchiniJ (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 5: e1000529.
40. SampsonJN, JacobsK, WangZ, YeagerM, ChanockS, et al. (2012) A two-platform design for next generation genome-wide association studies. Genet Epidemiol 36: 400–408.
41. AulchenkoYS, RipkeS, IsaacsA, van DuijnCM (2007) GenABEL: an R library for genome-wide association analysis. Bioinformatics 23: 1294–1296.
42. PurcellS, NealeB, Todd-BrownK, ThomasL, FerreiraMA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.